

INFECTION CONTROL^{AND}

HOSPITAL EPIDEMIOLOGY

Volume 11, Number 7 • July 1990

EDITORIAL POLICY STATEMENT

Duplicate Publication of a Manuscript 341

Richard P. Wenzel, MD, MSc;
Dennis G. Maki, MD; Sue Crow, MSN, RN, CIC;
William Schaffner, MD; John E. McGowan, Jr., MD

ORIGINAL ARTICLES

Control of Epidemic Methicillin-Resistant *Staphylococcus aureus* 343

Katherine A. Murray-Leisure, MD; Sandra Geib, RN;
Diane Graceley; Arline B. Rubin-Slutsky, RN;
Narendra Saxena, MD; H. Arnold Muller, MD;
Bruce H. Hamory, MD

Adverse Exposures and Universal Precautions Practices Among a Group of Highly Exposed Health Professionals 351

Mary E. Willy, MPH, BSN; Gita L. Dhillon, MS, CNM;
Nancy L. Loewen, MS, CNM; Robert A. Wesley, PhD;
David K. Henderson, MD

SPECIAL COMMENTARIES

The Influenza Vaccination Demonstration Project: An Expanded Policy Goal 357

David S. Fedson, MD

Infection Control for Home Health 362

Bryan Simmons, MD; Martha Trusler, RN;
Jane Roccaforte, MD; Philip Smith, MD;
Rebecca Scott, RN

AIDS

Risky Business: Using Necessarily Imprecise Casualty Counts to Estimate Occupational Risks for HIV-I Infection 371

Susan E. Beekmann, BS; Barbara J. Fahey, BSN;
Julie L. Gerberding, MD; David K. Henderson, MD

EMPORIATRICS

Emporiatics: Protecting Travelers From Malaria 380

Mary D. Nettleman, MD

STATISTICS FOR HOSPITAL EPIDEMIOLOGY

Practical Considerations in Designing Data Collection Forms 384

Patricia A. Wasek, BA

LETTERS TO THE EDITOR

Pseudoepidemic of *Rhodotorula rubra* in Patients Undergoing Fiberoptic Bronchoscopy 334

Marian Kennedy, RN
(Reply) William A. Rutala, PhD;
Karen K. Hoffmann, RN, MS; David J. Weber, MD

On Duplicate Publication of a Manuscript 336

W.H. Seto, MD; S.G. Ong, MD; T.Y. Ching, RN

SHEA NEWSLETTER 391

From SmithKline Biologicals/
Smith Kline & French Laboratories

Engerix-B®

Hepatitis B Vaccine (Recombinant)

0, 1, 2 Month Dosing Regimen for Certain Populations*

**20 mcg recombinant
dose helps to ensure
immune response
in adult patients of
all ages**

**Choice of dosing
regimens**

Adult dose (mcg)

Standard dosing regimen (0, 1 and 6
months)

**New 0, 1, 2 month dosing regimen for
certain populations***

Published efficacy data: Neonates born
of infected mothers†

VACTRAC™—computer software for
vaccination tracking and compliance

Bar-coded, unit-dose vials

Lowest cost per dose²

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

†Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beckman Corporation, 1990

Lowest Cost Per Dose²

Extensively Tested and Well Tolerated[‡]


State-of-the-art recombinant technology

14 million doses distributed in over 87 countries³

Switch to 'Engerix-B'

Can be used to complete a course of vaccination
initiated with another hepatitis B vaccine^{3,4}

| Engerix-B® | Recombivax HB®† |
|------------|-----------------|
| 20 | 10 |
| Yes | Yes |
| Yes | No |
| Yes | Yes |
| Yes | No |
| Yes | No |
| Yes | No |



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
Smith Kline & French Laboratories
Philadelphia, PA 19101

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SK&F literature or PDR. The following is a brief summary.

INDICATIONS AND USAGE: 'Engerix-B' is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are or will be, at increased risk of exposure to hepatitis B virus.

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

WARNINGS: Do not give additional injections to patients experiencing hypersensitivity after an 'Engerix-B' injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had a unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

PRECAUTIONS: General: As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with 'Engerix-B'. It is also not known whether 'Engerix-B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give 'Engerix-B' to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman.

Pediatric Use: 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well. maternally transferred antibodies do not interfere with the active immune response to the vaccine.

ADVERSE REACTIONS: 'Engerix-B' is generally well tolerated. During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix-B' and plasma-derived vaccines. In 36 clinical studies a total of 13,495 doses of 'Engerix-B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of 'Engerix-B'. Using a symptom checklist,* the most frequently reported adverse reactions were injection site soreness (22%), and fatigue* (14%). Other reactions are listed below.

Incidence 1% to 10% of injections: Induration; erythema; swelling; fever (> 37.5°); headache†; dizziness*.

*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

Incidence < 1% of injections: Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain/cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of 'Engerix-B' outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

Potential Adverse Experiences: In addition, certain other adverse experiences not observed with 'Engerix-B' have been reported with Hepavax B®† and/or Recombivax HB®‡. Those listed below are to serve as alerting information to physicians: Optic neuritis.

HOW SUPPLIED: 20 mcg/mL in Single-Dose Vials in packages of 1, 10 and 25 vials.

NDC 0007-3860-01 (package of 1)
NDC 0007-3860-11 (package of 10)
NDC 0007-3860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial.

NDC 0007-3859-01 (package of 1)

† plasma-derived, Hepatitis B Vaccine, MSD
‡ yeast-derived, Hepatitis B Vaccine, MSD

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium
Distributed by **SmithKline French Laboratories**
Division of SmithKline Beckman Corp., Philadelphia, PA 19101

Date of issuance Aug 1939

BAS-EB L6

© SmithKline Beckman Corporation, 1989

Engerix-B is a registered trademark of SmithKline Beckman Corporation

References:

1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBs antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide, December 1989.
3. Data on file, SK&F.
4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989; 10:689.

HATS OFF TO FIRST CLASS SERVICE

At SLACK Incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:

1-800-257-8290

Talk to a SLACK Customer Service Representative about:



Subscriptions. Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.




Renewals. Early subscription renewal helps avoid possible interruptions in service.

Change of Address. Please notify us four weeks in advance to assure prompt delivery to your new address.



Questions or Problems. Delivery problems or questions about your subscriptions can be handled instantly.



SLACK

6900 Grove Road,
Thorofare, NJ 08086

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

| | | | |
|---|---|-----|---------------------------------------|
| EDITORIAL POLICY STATEMENT | Duplicate Publication of a Manuscript | 341 | |
| | Richard P. Wenzel, MD, MSc; Dennis G. Maki, MD; Sue Crow, MSN, RN, CIC; William Schaffner, MD; John E. McGowan, Jr., MD; | | |
| ORIGINAL ARTICLES | Control of Epidemic Methicillin-Resistant <i>Staphylococcus aureus</i> | 343 | |
| | Katherine A. Murray-Leisure, MD; Sandra Geib, RN; Diane Graceley; Arline B. Rubin-Slutsky, RN; Narendra Saxena, MD; H. Arnold Muller, MD; Bruce H. Hamory, MD | | |
| | Adverse Exposures and Universal Precautions Practices Among a Group of Highly Exposed Health Professionals | 351 | |
| | Mary E. Willy, MPH, BSN; Gita L. Dhillon, MS, CNM; Nancy L. Loewen, MS, CNM; Robert A. Wesley, PhD; David K. Henderson, MD | | |
| SPECIAL SECTIONS | Special Commentaries | 357 | |
| | The Influenza Vaccination Demonstration Project: An Expanded Policy Goal | | |
| | David S. Fedson, MD | | |
| | Infection Control for Home Health | 362 | |
| | Bryan Simmons, MD; Martha Trusler, RN; Jane Roccaforte, MD; Philip Smith, MD; Rebecca Scott, RN | | |
| | AIDS | 371 | |
| | Risky Business: Using Necessarily Imprecise Casualty Counts to Estimate Occupational Risks for HIV-1 Infection | | |
| | Susan E. Beekmann, BS; Barbara J. Fahey, BSN; Julie L. Gerberding, MD; David K. Henderson, MD | | |
| | Emporiatrics | 380 | |
| | Emporiatrics: Protecting Travelers From Malaria | | |
| | Mary D. Nettleman, MD | | |
| | Statistics for Hospital Epidemiology | 384 | |
| | Practical Considerations in Designing Data Collection Forms | | |
| | Patricia A. Wasek, BA | | |
| DEPARTMENTS | Letters to the Editor | 334 | SHEA Newsletter 391 |
| | Calendar of Events | 390 | Classified Marketplace Cover 3 |

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

Copyright 1990: All rights reserved No part of this publication may be reproduced without written permission from the publisher

Subscriptions: Requests should be addressed to the publisher (except Japan) In Japan contact Woodbell Incorporated, 4-22-11, Kitakasai Edogawaku, Tokyo 134. Japan Subscription rates in the US and possessions Individual One year-\$60.00. Two years-\$95.00 Three years-\$125.00 Institutional One year-\$70.00 Two years-\$110.00. Three years-\$150.00. Canada \$18.00 additional each year. all other countries \$30.00 additional each year Single copies of current issues may be obtained for \$8.00, United States and possessions; \$16.00 all other countries

Reprints: All requests to reprint or use material published herein should be addressed to Lester J Robeson SLACK Incorporated, 6900 Grove Road Thorofare NJ 08086 For reprint orders and prices contact Fran Micaletti at (609) 848-1000 Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy plus 5.15 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970 This consent does not extend to other kinds of copying, such as for general distribution resale, advertising and promotional purposes or for creating new collective works

Change of address: Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road Thorofare, NJ 08086

As of Volume 1 Number 1 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents—Clinical Practice Hospital Literature index Cumulative Index to Nursing and Allied Health Literature and Nursing Abstracts

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS

Beyond Infection Control:

The New Hospital Epidemiology

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

| | |
|--------------------------------------|---|
| Jacques F. Acar, MD | Paris, France |
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Paul Arnow, MD | Chicago, Illinois |
| Graham A.J. Ayliffe, MD | Birmingham, United Kingdom |
| Neil L. Barg, MD | Yakima, Washington |
| Elizabeth Ann Bolyard, RN, MPH, CIC | Atlanta, Georgia |
| John M. Boyce, MD | Providence, Rhode Island |
| Professor Dr. Ilja Braveny | Munich, Federal Republic of Germany |
| Charles Bryan, MD | Columbia, South Carolina |
| Christian Brun-Buisson, MD | Creteil, France |
| Donald E. Craven, MD | Boston, Massachusetts |
| Sue Crow, MSN, RN, CIC | Shreveport, Louisiana |
| Franz Daschner, MD | Freiburg, Federal Republic of Germany |
| Leigh G. Donowitz, MD | Charlottesville, Virginia |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Bruce Farber, MD | Manhasset, New York |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Peter C. Fuchs, MD, PhD | Black Butte, Oregon |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Velvl Greene, PhD, MPH | Beer Sheva, Israel |
| Robert Gaynes, MD | Atlanta, Georgia |
| David W. Gregory, MD | Nashville, Tennessee |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | Los Angeles, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Marguerite McMillan Jackson, RN, PhD | San Diego, California |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| William R. Jarvis, MD | Atlanta, Georgia |
| Douglas S. Kernodle, MD | Nashville, Tennessee |
| Robert H. Latham, MD | Nashville, Tennessee |
| Lewis B. Lefkowitz, MD | Nashville, Tennessee |
| Hsieh-Shong Leu, MD, MSc | Taipei, Taiwan |
| Jack Levy, MD | Brussels, Belgium |
| Victor Lorian, MD | Bronx, New York |
| Dennis G. Maki, MD | Madison, Wisconsin |
| Professor Dr. Walter Marget | Munich, Federal Republic of Germany |
| William J. Martone, MD | Bethesda, Maryland |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Jonathan L. Meakins, MD, DSc | Montreal, Quebec, Canada |
| Raf Mertens, MD | Brussels, Belgium |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Trenton, New Jersey |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Theodore Sacks, MD | Jerusalem, Israel |
| William E. Scheckler, MD | Madison, Wisconsin |
| Kent Sepkowitz, MD | New York City, New York |
| Denis Spelman, MD | Prahran Victoria, Australia |
| Michael L. Tapper, MD | New York, New York |
| Clyde Thornsberry, PhD | Brentwood, Tennessee |
| Professor Leonid P. Titov | Minsk, Republic of Belarus |
| Timothy R. Townsend, MD | Millwood, Virginia |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Professor Wang Shu-Qun | Beijing, People's Republic of China |
| J. John Weems, Jr., MD | Greenville, South Carolina |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Professor Dr. W. Weuffen | Greifswald, Federal Republic of Germany |
| Sergio B. Wey, MD | São Paulo, Brazil |
| Rebecca Wurtz, MD | Evanston, Illinois |

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

"Synergism.."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantially less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temperature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77° F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* Journal of Clinical Microbiology,
November 1985, p. 735 - 739



Sporicidin
INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847